Effect of LY3154207 on Cognition in Mild-to-ModerateDementia Due to Lewy Body Dementia (LBD) Associated with Idiopathic Parkinson's Disease (PD) or Dementia with Lewy Bodies (DLB) Save

Date Added
November 13th, 2018
PRO Number
Pro00075666
Researcher
Federico Rodriguez-porcel

List of Studies

Silhouette
Keywords
Dementia, Parkinsons
Summary

Study I7S-MC-HBEH (HBEH) is a multicenter, randomized (i.e. study in which people are assigned at random (by chance alone) to receive one of several clinical interventions), double-blind (i.e., neither the participant nor the person evaluating for the study knows what group the participant has been assigned to), parallel-group (i.e., a type of study where two groups of treatments, A and B, are given so that one group receives only A while another group receives only B.), placebo-controlled (i.e. one group will receive the study drug and the other will receive a substance that has no therapeutic effect, also known as placebo), fixed-dosage (i.e., the dosage will not change during the course of the study), Phase 2a study (i.e., a trial with the objective of assessing what dose is more effective in treating symptoms.) comparing various dosages of LY3154207 administered orally once a day with placebo over 12 weeks in subjects with mild-to-moderate Parkinson disease dementia (PDD).

The study includes a Screening Period (Visits 1 to 2) of a minimum of 7 days and up to 14 days, a 14-day Pretreatment Period (Visits 2 to 3), a 12-week Treatment Period (Visits 3 to 11), and a 14-day Safety Follow-Up Period (Visit 12).

Your participation will last about 17-18 weeks.

The purpose of this study is to find out how LY3154207 compares with placebo in treating memory and thinking problems in individuals with mild-to-moderate Parkinson's disease dementia.

Institution
MUSC
Recruitment Contact
Danielle Helms
843-792-8327
helmsda@musc.edu

Connectome Biomarkers for Predicting Alzheimer's Risk in Traumatic Brain Injury Save

Date Added
July 17th, 2018
PRO Number
Pro00077915
Researcher
Jane Joseph

List of Studies


Profiles_link
Keywords
Aging, Alzheimers, Brain, Dementia, Healthy Volunteer Studies, Memory Loss, Military
Summary

Traumatic Brain Injury is a risk factor for Alzheimer's Disease and other dementias. This study will use neuroimaging in Veterans and civilians with a history of TBI or without TBI to understand whether some of the brain changes that occur in Alzheimer's Disease are present in people with a history of TBI. The study is recruiting male and female military Veterans or civilians with or without TBI between the ages of 30 and 65.

Institution
MUSC
Recruitment Contact
Laura Lohnes
843-792-7709
lohnes@musc.edu

Using Connectomics to Characterize Risk for Alzheimer's Disease Save

Date Added
October 17th, 2017
PRO Number
Pro00071249
Researcher
Jane Joseph

List of Studies


Profiles_link
Keywords
Alzheimers, Dementia
Summary

This study will use neuroimaging to understand how the connections in the brain change in Alzheimer's Disease. Changes will also be examined in individuals with mild cognitive impairment and healthy aging. The goal is to discover which brain changes are present in healthy aging and MCI so that future studies can assess the risk for developing Alzheimer's Disease. The study involves 3 visits to MUSC: a screening visit for cognitive testing and neuroimaging, a second visit for additional neuroimaging for those who qualify for the study, and a 6-month follow-up visit for cognitive testing.

Institution
MUSC
Recruitment Contact
Laura Lohnes
8437927709
lohnes@musc.edu

Change_preferences

-- OR --

Create_login